Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia

Despite high initial response rates, acute myeloid leukemia (AML) treated with the BCL-2–selective inhibitor venetoclax (VEN) alone or in combinations commonly acquires resistance. We performed gene/protein expression, metabolomic and methylation analyses of isogenic AML cell lines sensitive or resi...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Qi, Riley-Gillis, Bridget, Han, Lina, Jia, Yannan, Lodi, Alessia, Zhang, Haijiao, Ganesan, Saravanan, Pan, Rongqing, Konoplev, Sergej N., Sweeney, Shannon R., Ryan, Jeremy A., Jitkova, Yulia, Dunner, Kenneth, Grosskurth, Shaun E., Vijay, Priyanka, Ghosh, Sujana, Lu, Charles, Ma, Wencai, Kurtz, Stephen, Ruvolo, Vivian R., Ma, Helen, Weng, Connie C., Ramage, Cassandra L., Baran, Natalia, Shi, Ce, Cai, Tianyu, Davis, Richard Eric, Battula, Venkata L., Mi, Yingchang, Wang, Jing, DiNardo, Courtney D., Andreeff, Michael, Tyner, Jeffery W., Schimmer, Aaron, Letai, Anthony, Padua, Rose Ann, Bueso-Ramos, Carlos E., Tiziani, Stefano, Leverson, Joel, Popovic, Relja, Konopleva, Marina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8858957/
https://www.ncbi.nlm.nih.gov/pubmed/35185150
http://dx.doi.org/10.1038/s41392-021-00870-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8858957/
https://www.ncbi.nlm.nih.gov/pubmed/35185150
http://dx.doi.org/10.1038/s41392-021-00870-3

Ejemplares similares